Melasma in darker skin tones: why it's harder to treat and what actually works

Melasma is the one that comes back.

Patients describe the same arc. Something works. The patches across the cheeks or above the lip fade over a few months, they stop the routine or take a summer trip, and it returns to roughly where it started. After the second or third cycle they arrive assuming the problem is them, or that they simply haven't found the right product yet.

Neither is it. Melasma recurs because of what it actually is, and most explanations of it are describing the wrong layer of the skin.

What melasma is

Melasma appears as symmetric brown to gray-brown patches, most often across the cheeks, forehead, upper lip and jawline. It is strongly associated with sun exposure, with hormonal shifts including pregnancy and oral contraceptives, and with genetics. It overwhelmingly affects women, and it is far more common in people with darker skin.

That much is in every patient handout. The part that usually gets left out is what is happening underneath.

It is not a melanocyte problem

If melasma were simply melanocytes making too much pigment, suppressing melanocytes would fix it. That approach has been tried exhaustively for decades, and it does not hold.

Biopsy studies tell a different story. In one review of the dermal pathology, 95.8 percent of melasma lesions showed damage to the basement membrane, the structural boundary separating epidermis from dermis.¹ When that boundary is compromised, pigment cells and pigment itself can migrate downward into territory they were never meant to occupy. Pendulous melanocytes, which hang down into the dermis, were found in 76 percent of lesional biopsies compared with 42 percent of adjacent skin.¹

The dermis in melasma is altered in other ways too. Mast cell numbers are increased, releasing histamine and tryptase that both stimulate pigment production and degrade collagen. Vessel density, vessel size and VEGF expression are all elevated, consistent with ongoing low-grade inflammation. Solar elastosis, the accumulated signature of ultraviolet damage, appeared in 83 percent of melasma skin against 29 percent of neighboring skin.¹ Senescent fibroblasts, aging cells that secrete pigment-promoting signals, appear to contribute as well.

Why that explains how melasma behaves

Read that list again and every frustrating thing about this condition becomes predictable.

It recurs because the structural damage is still there when the pigment fades. Nothing about lightening the surface repairs a basement membrane. Single agents disappoint because they address one node in a system with at least five, which is why the authors of that review conclude melasma "is often recalcitrant and requires a multimodal approach."¹ And it is genuinely photoaging-associated, not merely sun-triggered, which is why it tends to worsen across decades rather than resolving with age.

This also reframes what success looks like. Melasma is a chronic relapsing condition, and the goal is durable control rather than cure. I would rather say that at the first visit than let someone discover it on their own after their third relapse.

Why it is harder in darker skin

Three things compound.

There is more pigment to begin with, so the same degree of melanocyte overactivity produces a more visible result. There is more often a dermal component, and dermal pigment resists topical therapy because most topicals act on the epidermis. And the treatments themselves carry more risk, because peels and lasers that irritate can trigger post-inflammatory hyperpigmentation layered on top of the melasma you were treating.

That third point is the one that turns a manageable condition into a two-year problem, and it is the reason conservative treatment is not timidity here. It is the strategy.

The light problem is bigger than UV

If you take one practical thing from this article, take this one.

Most people treat sunscreen as an ultraviolet question. For melasma in skin of color, visible light matters too, and it is significantly underrecognized as a driver of hyperpigmentation.² A conventional untinted sunscreen, however high its SPF, does very little about visible light. SPF only describes UVB.

Iron oxides block visible light, which is why they are added to tinted sunscreens. Tinted formulations containing iron oxides are more effective than untinted ones at preventing melasma relapse and reducing hyperpigmentation, and they appear to improve the performance of topical hydroquinone alongside them.² The guidance in skin of color is direct: recommend tinted sunscreens with iron oxides over untinted ones.²

This is a genuinely cheap intervention that changes outcomes, and it is missed constantly. Screens, indoor lighting and daylight through a window all deliver visible light. If your sunscreen has no tint, it is doing half the job.

What actually works

Treatment is layered, and it is measured in months.

Photoprotection is the foundation, not a supporting player, and it should be tinted for the reasons above. Every other agent is working against light exposure.

Topical therapy remains the core. Hydroquinone, usually in a triple combination with a retinoid and a short course of a low-potency corticosteroid, has the longest record of any approach. Azelaic acid, cysteamine, niacinamide and topical tranexamic acid are all reasonable additions or alternatives, and combinations outperform single agents for the structural reasons already described.

Oral tranexamic acid is the most meaningful addition to melasma treatment in years. A network meta-analysis of six randomized trials covering 599 patients identified 750 mg per day, given as 250 mg three times daily for twelve weeks, as the optimal regimen, with 250 mg twice daily an acceptable option for patients likely to struggle with adherence.³ Serious thromboembolic complications were rare at these doses, which are far below those used in coagulation medicine, though gastrointestinal upset and lighter periods are commonly reported.³

That said, tranexamic acid is an antifibrinolytic, and it is a prescription medication that requires a real history before it is written. Personal or family history of clotting, current hormonal contraception, smoking, immobility, recent surgery and pregnancy all belong in that conversation. Anyone offering it without taking that history is skipping the part that matters.

Where peels and lasers fit

Cautiously, and usually late.

Melasma is notorious for being made worse by aggressive procedural treatment. Superficial chemical peels can help as an adjunct once topical therapy has stabilized things. Lasers can be useful at low fluence with conservative settings, and the 1064 nm Nd:YAG is the usual choice in deeper skin for the reasons covered in a separate article.

But the failure mode here is specific and common: a device is used at settings appropriate to a different problem, the skin responds with inflammation, and the patient leaves with melasma plus post-inflammatory hyperpigmentation. In a condition where the basement membrane is already damaged in nearly every lesion, adding thermal injury is not an obviously good idea. Procedures should follow topical control rather than substitute for it.

What to expect

A realistic plan runs on months, layers several agents, treats sun protection as treatment rather than advice, and assumes maintenance rather than a finish line. Relapse after a summer, a pregnancy or a lapse in photoprotection is the expected behavior of the condition, not evidence that the plan failed.

Melasma responds well to patience and consistency. It punishes impatience more reliably than almost anything else we treat.